BioCentury | Dec 19, 2019

Combined inhibition of EIF4A1 and glutaminase for pancreatic cancer

...CATEGORY: Cancer INDICATION: Pancreatic cancer Inhibiting the translation initiator EIF4A1 and the glutamine metabolism enzyme GLS...
...in patient-derived PDAC cell lines. Treatment with a GLS inhibitor tool compound or CB-839, a GLS...
...eFT226) in Phase I/II testing for solid tumors. TARGET/MARKER/PATHWAY: Eukaryotic translation initiation factor 4A1 (EIF4A1); glutaminase (GLS)...
BioCentury | Dec 6, 2019
Targets & Mechanisms

Emerging immuno-oncology mechanisms at ASH 2019

...dropping from four to zero mentions. Metabolism targets with the biggest increases were SLC2A1 and GLS...
BioCentury | Aug 29, 2019
Clinical News

Aug. 29 Clinical Quick Takes: Immunicum's off-the-shelf cell therapy misses in Phase II for kidney cancer; plus Acurx and Esperion

...with PDUFA dates of Feb. 21, 2020 and Feb. 26, 2020, respectively. Sandi Wong, Staff Writer ACX-362E (GLS-362E) bempedoic...
BioCentury | Jun 18, 2019
Clinical News

June 17 Clinical Quick Takes: VBI's HBV vaccine misses secondary endpoint, plus ArQule, Verastem and more

...Calithera Biosciences Inc. (NASDAQ:CALA) announced top-line results from the Phase II ENTRATA study of its glutaminase (GLS)...
BioCentury | Apr 10, 2019
Distillery Therapeutics

Diazooxohexanoate-based prodrug of a GLS inhibitor for lymphoma

...DISEASE CATEGORY: Cancer INDICATION: Lymphoma Cell culture studies identified a diazooxohexanoate-based prodrug of a GLS inhibitor...
...inhibitor that could help treat lymphoma. Chemical synthesis and screening of ester prodrugs of the GLS...
...include testing the prodrug in mouse models of lymphoma. Calithera Biosciences Inc. has CB-839, a GLS...
BioCentury | Nov 30, 2018
Targets & Mechanisms

Revving up metabolism at ASH 2018

...ACC1) 3 Fatty acid synthase (FASN; FAS) 3 ATP citrate lyase (ACLY) 2 Glutamine pathway Glutaminase (GLS)...
BioCentury | Nov 15, 2018
Product R&D

Tempest takes PPAR alpha into cancer

...candidate CB-839 blocks the glutamine-metabolizing enzyme GLS, and Dracen Pharmaceuticals Inc. has preclinical antagonists of GLS...
...1 FASN (FAS) - Fatty acid synthase FGF21 - Fibroblast growth factor 21 GLS - Glutaminase...
BioCentury | Sep 28, 2018
Targets & Mechanisms

Cell metabolism’s migration

...Christofk, UCLA At least two companies have compounds targeting the glutamine pathway: the small molecule GLS...
...Angeles, Calif. Targets CRAF (RAF1) EGFR (ErbB1; HER1) - Epidermal growth factor receptor GLS - Glutaminase...
BioCentury | Sep 20, 2018
Distillery Therapeutics

Cancer

...INDICATION: Brain cancer Cell culture and mouse studies suggest inhibiting GLS could enhance the efficacy of...
...ROS)-inducing drugs in IDH1-mutant glioma. In a human glioma cell line expressing mutant IDH1, the GLS...
...I testing for hematologic malignancies and leukemia, and preclinical testing for multiple myeloma (MM). TARGET/MARKER/PATHWAY: Glutaminase (GLS)...
BioCentury | Aug 31, 2018
Financial News

Harbin Gloria selling stake in biotech unit to new investors

...biopharmaceutical products. In July, Harbin Gloria transferred to Guangzhou Gloria rights to an anti-PD-1 antibody GLS-010...
...cell technology and providing chemical engineering services. Guangzhou Gloria is conducting Phase II studies of GLS-010...
...gained RMB0.39 to RMB4.59 on Aug. 17. Harbin Gloria Pharmaceuticals Co. Ltd. (SZSE:002437), Harbin, China Mary Romeo GLS-010...
Items per page:
1 - 10 of 62